Finasteride Improves the Sensitivity of Digital Rectal Examination for Prostate Cancer Detection

Journal of Urology

Volumn 177, Issue 5, 2007, Pages 1749-1752

  Thompson, Ian M ^a   Tangen, Catherine M ^d   Goodman, Phyllis J ^d   Lucia, M Scott ^e   Parnes, Howard L ^f   Lippman, Scott M ^c   Coltman Jr , Charles A ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b Southwest Oncology Group   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

digital rectal examination; finasteride; mass screening; prostate; prostatic neoplasms

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; DIGITAL RECTAL EXAMINATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 34147183350     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.071     Document Type: Article

References (8)

1. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A.G., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97 (2005) 1407
2. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529
3. Schroder F.H., Raaijmakers R., Postma R., van der Kwast T.H., and Roobol M.J. 4-Year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 174 (2005) 489
4. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
5. Thompson I.M., Chi C., Ankerst D.P., Goodman P.J., Tangen C.M., Lippman S.M., et al. The effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128
6. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
7. Goodman P.J., Thompson Jr. I.M., Tangen C.M., Crowley J.J., Ford L.G., and Coltman Jr. C.A. The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol 175 (2006) 2234
8. Issa M.M., Zasada W., Ward K., Hall J.A., Petros J.A., Ritenour C.W.M., et al. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States veterans referred for prostate biopsy. Cancer Detect Prevent 30 (2006) 269